How are Invega Sustenna adverse event reports trending over time?
This graph shows volume of adverse events submitted to the FDA by quarter for Invega Sustenna, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Invega Sustenna is flagged as the suspect drug causing the adverse event.
What are the most common Invega Sustenna adverse events reported to the FDA?
Product Quality Issue | 337 (3.7%) |
Drug Dose Omission | 316 (3.47%) |
Drug Ineffective | 253 (2.78%) |
Inappropriate Schedule Of Drug Admi... | 226 (2.48%) |
Weight Increased | 172 (1.89%) |
Injection Site Nodule | 158 (1.73%) |
Psychotic Disorder | 148 (1.62%) |
Injection Site Pain | 144 (1.58%) |
Condition Aggravated | 132 (1.45%) |
Incorrect Dose Administered | 119 (1.31%) |
Device Leakage | 115 (1.26%) |
![]() |
Share/Embed Graph
Export Data
This graph shows the top adverse events submitted to the FDA for Invega Sustenna, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Invega Sustenna is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
What are the most common Invega Sustenna adverse events reported to the FDA?
Medication Errors | 1010 (11.08%) |
Administration Site Reactions | 688 (7.55%) |
Therapeutic And Nontherapeutic Effe... | 504 (5.53%) |
Movement Disorders | 429 (4.71%) |
Neurological | 397 (4.36%) |
Product Quality Issues | 347 (3.81%) |
Schizophrenia And Other Psychotic | 268 (2.94%) |
Procedural And Device Related Injur... | 238 (2.61%) |
Personality Disorders | 232 (2.55%) |
Disturbances In Thinking | 231 (2.53%) |
Physical Examination Topics | 227 (2.49%) |
![]() |
Share/Embed Graph
Export Data
This graph shows the top categories of adverse events submitted to the FDA for Invega Sustenna, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Invega Sustenna is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
Why are people taking Invega Sustenna, according to those reporting adverse events to the FDA?
Product Used For Unknown Indication | 1285 |
Schizophrenia | 1094 |
Schizoaffective Disorder | 232 |
Drug Use For Unknown Indication | 168 |
Bipolar Disorder | 150 |
Psychotic Disorder | 114 |
![]() |
Label | Labeler | Effective |
---|---|---|
Invega Sustenna | Janssen Pharmaceuticals, Inc. | 22-OCT-12 |
What Invega Sustenna safety concerns are being reported by doctors and researchers in the medical literature?
This report contains aggregated drug side effects and adverse events for Invega Sustenna. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.
DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.
DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.
Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.
Share your experience with Invega Sustenna.